The trial will monitor patients across Europe for 24 months as they are treated with tildrakizumab

Company’s candidate, in combination with MSD’s Keytruda, receives PRIME designation

Treatment concerns adults and adolescents with stage IIB or IIC melanoma skin cancer

Updated Date: Mon, 03 Apr 2023 00:00:00 EDT

Updated Date: Mon, 03 Apr 2023 00:00:00 EDT

Updated Date: Mon, 03 Apr 2023 00:00:00 EDT

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and […]

Updated Date: Thu, 30 Mar 2023 00:00:00 EDT

Updated Date: Thu, 30 Mar 2023 00:00:00 EDT

Updated Date: Thu, 30 Mar 2023 00:00:00 EDT